Adult Acute Myeloblastic Leukemia With Maturation (M2) [clinicaltrials_resource:74e023e5e4e8517f81a8b47cd54341ed]
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00003190]Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00006363]Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00027872]Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00045435]S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00093418]XK469R in Treating Patients With Refractory Hematologic Cancer [clinicaltrials:NCT00095797]clinicaltrials:NCT00096122Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00096148]Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes [clinicaltrials:NCT00098423]SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes [clinicaltrials:NCT00098826]Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00101231]Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [clinicaltrials:NCT00101296]17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [clinicaltrials:NCT00103272]Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT00112853]Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia [clinicaltrials:NCT00131989]7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes [clinicaltrials:NCT00301938]clinicaltrials:NCT00305773clinicaltrials:NCT00352365Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [clinicaltrials:NCT00357305]clinicaltrials:NCT00407966MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia [clinicaltrials:NCT00462605]Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia [clinicaltrials:NCT00470197]clinicaltrials:NCT00602771clinicaltrials:NCT00634244clinicaltrials:NCT00666588Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [clinicaltrials:NCT00673153]clinicaltrials:NCT00742625clinicaltrials:NCT00795002clinicaltrials:NCT00895934Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT01031368]Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia [clinicaltrials:NCT01127009]Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia [clinicaltrials:NCT01159301]High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma [clinicaltrials:NCT01177371]Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy [clinicaltrials:NCT01235572]Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant [clinicaltrials:NCT01252667]clinicaltrials:NCT01253447Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy [clinicaltrials:NCT01307579]clinicaltrials:NCT01342887Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT01349972]clinicaltrials:NCT01521936
condition [clinicaltrials_vocabulary:condition]
Adult Acute Myeloblastic Leukemia With Maturation (M2) [clinicaltrials_resource:74e023e5e4e8517f81a8b47cd54341ed]
Bio2RDF identifier
74e023e5e4e8517f81a8b47cd54341ed
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:74e023e5e4e8517f81a8b47cd54341ed
identifier
clinicaltrials_resource:74e023e5e4e8517f81a8b47cd54341ed
title
Adult Acute Myeloblastic Leukemia With Maturation (M2)
@en
label
Adult Acute Myeloblastic Leuke ...... 023e5e4e8517f81a8b47cd54341ed]
@en